CHICAGO--(BUSINESS WIRE)--NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, will present results from the NantOmics pharmacogenomics test, an integrative panomic approach to pharmacogenomics screening, during the developmental therapeutics session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event bringing together 30,000 oncology professionals from June 1-5, 2018 at McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at booth #7147 during the event.
“Our goal was to develop a more effective way to accurately detect pharmacogenomic variants in oncology patients,” said Patrick Soon-Shiong, MD, founder of NantWorks. “We are excited to share how we’re not only fulfilling this industry need with our pharmacogenomics test, but also how we’re tailoring therapies to a patient’s specific genotype in order to optimize testing.”
Presentation Details
The
NantOmics Pharmacogenomics Test: An integrative panomic approach to
pharmacogenomics screening, Abstract #2575
WHO:
NantOmics, LLC and NantKwest, LLC
WHAT: Developmental
Therapeutics Session
WHEN: June 4, 8:00-11:30 AM CST
WHERE:
Hall A, McCormick Place
Presentation Summary
Pharmacogenomics screening was performed on whole genome and whole exome sequencing data of FFPE tumors and their matched normal tissues from 1,879 oncology patients. The test observed how allele frequencies correspond well to known population frequencies, and validation studies demonstrated that the test detects each variant in a panel, and correctly determines patient genotype in all studied cases. Given the high percentage of patients with potentially treatment-altering genomic variants, these results underscore the need for more routine pharmacogenomics screening in the oncological setting.
About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular analysis capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular analysis company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis. For more information please visit www.nantomics.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
